Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Short Interest Update

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was the target of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,351,800 shares, a decline of 7.4% from the June 30th total of 2,540,100 shares. Currently, 2.9% of the company’s shares are short sold. Based on an average trading volume of 835,700 shares, the short-interest ratio is currently 2.8 days.

Shares of REGN stock traded up $3.74 during trading on Friday, reaching $296.85. The company’s stock had a trading volume of 647,759 shares, compared to its average volume of 792,509. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.88 and a quick ratio of 3.11. The company has a market capitalization of $31.94 billion, a price-to-earnings ratio of 14.99, a P/E/G ratio of 1.39 and a beta of 1.15. The stock’s 50-day moving average price is $304.13 and its 200 day moving average price is $350.53. Regeneron Pharmaceuticals has a 1-year low of $287.66 and a 1-year high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.60 by $0.69. The firm had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.45 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 19.22 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on REGN shares. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals to $344.00 and set a “market perform” rating on the stock in a research note on Wednesday, August 7th. Cantor Fitzgerald reduced their price target on shares of Regeneron Pharmaceuticals from $441.00 to $405.00 and set a “neutral” rating on the stock in a research note on Monday, May 13th. Piper Jaffray Companies reissued an “overweight” rating and issued a $435.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 7th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, June 21st. Finally, Cowen reissued a “hold” rating and issued a $353.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and an average target price of $398.25.

Several hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its holdings in Regeneron Pharmaceuticals by 3.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 183,437 shares of the biopharmaceutical company’s stock worth $68,499,000 after acquiring an additional 5,971 shares during the last quarter. Geode Capital Management LLC grew its position in Regeneron Pharmaceuticals by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock worth $402,138,000 after purchasing an additional 78,143 shares during the period. Virtu Financial LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $384,000. Retirement Systems of Alabama grew its position in Regeneron Pharmaceuticals by 2.1% in the 1st quarter. Retirement Systems of Alabama now owns 36,495 shares of the biopharmaceutical company’s stock worth $14,986,000 after purchasing an additional 760 shares during the period. Finally, Quantitative Systematic Strategies LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $202,000. Hedge funds and other institutional investors own 66.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: Return on Equity (ROE)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.